|By PR Newswire||
|April 9, 2014 06:28 AM EDT||
NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.
- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in India.
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 18
4 Disease Management 19
4.1 Treatment Overview 20
4.2 India 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles - Major Brands 29
5.3.1 Remicade (infliximab) 29
5.3.2 Other Marketed Products 35
6 Opportunity and Unmet Need 36
6.1 Overview 36
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37
6.3 More Therapies for Anti-TNF-Refractory Patients 38
6.4 Unmet Needs Gap Analysis 39
6.5 Targeted Therapies 40
6.6 Predictive Tools for Early Diagnosis and Treatment 41
7 Pipeline Assessment 42
7.1 Overview 42
7.2 Promising Drugs in Clinical Development 42
7.3 Other Late-Stage Pipeline Products 44
7.3.1 Cx601 44
7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46
8 Market Outlook 51
8.1 Global Markets 51
8.1.1 Drivers and Barriers - Global Issues 51
9 India 56
9.1 Forecast 56
9.2 Key Events 58
9.3 Drivers and Barriers 59
9.3.1 Driver: Continued investment in the national healthcare system and services 59
9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59
9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60
9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60
9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61
10 Appendix 62
10.1 Bibliography 62
10.2 Abbreviations 67
10.3 Methodology 71
10.4 Forecasting Methodology 71
10.4.1 Diagnosed CD Patients 71
10.4.2 Percent Drug-Treated Patients 72
10.4.3 Drugs Included in Each Therapeutic Class 72
10.4.4 General Pricing Assumptions 72
10.4.5 Individual Drug Assumptions 74
10.4.6 Generic Erosion 74
10.5 Physicians and Specialists Included in This Study 75
10.6 Primary Research - Prescriber Survey 76
10.7 About the Authors 77
10.7.1 Author/Reviewer 77
10.7.2 Global Head of Healthcare 77
10.8 About GlobalData 78
10.9 Disclaimer 78
1.1 List of Tables
Table 1: Symptoms of CD 17
Table 2: Treatment Guidelines for CD 21
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23
Table 4: Leading Branded Drugs Used to Treat CD 29
Table 5: Product Profile - Remicade 31
Table 6: Remicade SWOT Analysis, 2013 34
Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35
Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37
Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40
Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42
Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43
Table 12: Product Profile - Cx601 45
Table 13: Cx601 SWOT Analysis, 2013 46
Table 14: Product Profile - RHB-104 48
Table 15: RHB-104 SWOT Analysis, 2013 50
Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51
Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57
Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58
Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59
Table 20: Physicians Surveyed, By Country 76
1.2 List of Figures
Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13
Figure 2: Potential Biologic Drug Targets for CD 16
Figure 3: Patient Care Path for CD 22
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43
Figure 5: Sales for CD in India by Drug Class, 2012-2022 58
To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
In the 21st century, security on the Internet has become one of the most important issues. We hear more and more about cyber-attacks on the websites of large corporations, banks and even small businesses. When online we’re concerned not only for our own safety but also our privacy. We have to know that hackers usually start their preparation by investigating the private information of admins – the habits, interests, visited websites and so on. On the other hand, our own security is in danger bec...
Oct. 26, 2016 02:45 PM EDT Reads: 313
Successful transition from traditional IT to cloud computing requires three key ingredients: an IT architecture that allows companies to extend their internal best practices to the cloud, a cost point that allows economies of scale, and automated processes that manage risk exposure and maintain regulatory compliance with industry regulations (FFIEC, PCI-DSS, HIPAA, FISMA). The unique combination of VMware, the IBM Cloud, and Cloud Raxak, a 2016 Gartner Cool Vendor in IT Automation, provides a co...
Oct. 26, 2016 02:15 PM EDT Reads: 1,283
SYS-CON Events announced today that Embotics, the cloud automation company, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Embotics is the cloud automation company for IT organizations and service providers that need to improve provisioning or enable self-service capabilities. With a relentless focus on delivering a premier user experience and unmatched customer support, Embotics is the fas...
Oct. 26, 2016 02:00 PM EDT Reads: 993
SYS-CON Events announced today that MathFreeOn will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MathFreeOn is Software as a Service (SaaS) used in Engineering and Math education. Write scripts and solve math problems online. MathFreeOn provides online courses for beginners or amateurs who have difficulties in writing scripts. In accordance with various mathematical topics, there are more tha...
Oct. 26, 2016 01:30 PM EDT Reads: 1,107
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Oct. 26, 2016 01:15 PM EDT Reads: 1,391
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Oct. 26, 2016 01:00 PM EDT Reads: 5,010
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, will discuss how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team a...
Oct. 26, 2016 12:45 PM EDT Reads: 605
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Service consists of a public key service and a private key escrow service.
Oct. 26, 2016 12:45 PM EDT Reads: 1,164
OnProcess Technology has announced it will be a featured speaker at @ThingsExpo, taking place November 1 - 3, 2016, in Santa Clara, California. Dan Gettens, OnProcess’ Chief Analytics Officer, will discuss how Internet of Things (IoT) data can be leveraged to predict product failures, improve uptime and slash costly inventory stock. @ThingsExpo is an annual gathering of IoT and cloud developers, practitioners and thought-leaders who exchange ideas and insights on topics ranging from Big Data in...
Oct. 26, 2016 12:45 PM EDT Reads: 414
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
Oct. 26, 2016 12:45 PM EDT Reads: 8,557
SYS-CON Events announced today that Cemware will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Use MATLAB functions by just visiting website mathfreeon.com. MATLAB compatible, freely usable, online platform services. As of October 2016, 80,000 users from 180 countries are enjoying our platform service.
Oct. 26, 2016 12:30 PM EDT Reads: 946
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Oct. 26, 2016 12:30 PM EDT Reads: 3,955
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
Oct. 26, 2016 12:15 PM EDT Reads: 1,603
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Oct. 26, 2016 12:15 PM EDT Reads: 2,228
Digitization is driving a fundamental change in society that is transforming the way businesses work with their customers, their supply chains and their people. Digital transformation leverages DevOps best practices, such as Agile Parallel Development, Continuous Delivery and Agile Operations to capitalize on opportunities and create competitive differentiation in the application economy. However, information security has been notably absent from the DevOps movement. Speed doesn’t have to negat...
Oct. 26, 2016 12:00 PM EDT Reads: 2,900